These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9432125)

  • 1. Structural and functional analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in neuroblastoma.
    Iolascon A; Giordani L; Moretti A; Tonini GP; Lo Cunsolo C; Mastropietro S; Borriello A; Ragione FD
    Pediatr Res; 1998 Jan; 43(1):139-44. PubMed ID: 9432125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
    Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
    Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of CDKN2A, CDKN2B, CDKN2C, and cyclin Ds gene status in hepatoblastoma.
    Iolascon A; Giordani L; Moretti A; Basso G; Borriello A; Della Ragione F
    Hepatology; 1998 Apr; 27(4):989-95. PubMed ID: 9537438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of CDKN2A(p16)/CDKN2B(p15) alterations and homozygous chromosome arm 9p deletions in human lung carcinoma.
    Hamada K; Kohno T; Kawanishi M; Ohwada S; Yokota J
    Genes Chromosomes Cancer; 1998 Jul; 22(3):232-40. PubMed ID: 9624535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of evidence for mutations or deletions in the CDKN2A/p16 and CDKN2B/p15 genes of Brazilian neuroblastoma patients.
    Bassi CL; Martelli L; Cipolotti R; Scrideli CA; Defávery R; Tone LG
    Braz J Med Biol Res; 2004 Nov; 37(11):1683-7. PubMed ID: 15517085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intragenic mutations of CDKN2B and CDKN2A in primary human esophageal cancers.
    Suzuki H; Zhou X; Yin J; Lei J; Jiang HY; Suzuki Y; Chan T; Hannon GJ; Mergner WJ; Abraham JM
    Hum Mol Genet; 1995 Oct; 4(10):1883-7. PubMed ID: 8595411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infrequent mutations and no methylation of CDKN2A (P16/MTS1) and CDKN2B (p15/MTS2) in hepatocellular carcinoma in Taiwan.
    Lin YW; Chen CH; Huang GT; Lee PH; Wang JT; Chen DS; Lu FJ; Sheu JC
    Eur J Cancer; 1998 Oct; 34(11):1789-95. PubMed ID: 9893670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic DNA and messenger RNA expression alterations of the CDKN2B and CDKN2 genes in esophageal squamous carcinoma cell lines.
    Zhou X; Suzuki H; Shimada Y; Imamura M; Yin J; Jiang HY; Tarmin L; Abraham JM; Meltzer SJ
    Genes Chromosomes Cancer; 1995 Aug; 13(4):285-90. PubMed ID: 7547637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oligodendroglial tumors frequently demonstrate hypermethylation of the CDKN2A (MTS1, p16INK4a), p14ARF, and CDKN2B (MTS2, p15INK4b) tumor suppressor genes.
    Wolter M; Reifenberger J; Blaschke B; Ichimura K; Schmidt EE; Collins VP; Reifenberger G
    J Neuropathol Exp Neurol; 2001 Dec; 60(12):1170-80. PubMed ID: 11764089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
    Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
    Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single nucleotide polymorphism in the 3'untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare.
    Kumar R; Smeds J; Berggren P; Straume O; Rozell BL; Akslen LA; Hemminki K
    Int J Cancer; 2001 Nov; 95(6):388-93. PubMed ID: 11668523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization of 9p21 deletions shows a minimal common deleted region removing CDKN2A exon 1 and CDKN2B exon 2 in diffuse large B-cell lymphomas.
    Guney S; Bertrand P; Jardin F; Ruminy P; Kerckaert JP; Tilly H; Bastard C
    Genes Chromosomes Cancer; 2011 Sep; 50(9):715-25. PubMed ID: 21638516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The p16 and p18 tumor suppressor genes in neuroblastoma: implications for drug resistance.
    Diccianni MB; Chau LS; Batova A; Vu TQ; Yu AL
    Cancer Lett; 1996 Jul; 104(2):183-92. PubMed ID: 8665486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes.
    Guney S; Jardin F; Bertrand P; Mareschal S; Parmentier F; Picquenot JM; Tilly H; Bastard C
    Genes Chromosomes Cancer; 2012 Sep; 51(9):858-67. PubMed ID: 22619049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor suppressor genes in the 9p21 gene cluster are selective targets of inactivation in neuroendocrine gastroenteropancreatic tumors.
    Lubomierski N; Kersting M; Bert T; Muench K; Wulbrand U; Schuermann M; Bartsch D; Simon B
    Cancer Res; 2001 Aug; 61(15):5905-10. PubMed ID: 11479232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma.
    Platz A; Hansson J; Månsson-Brahme E; Lagerlof B; Linder S; Lundqvist E; Sevigny P; Inganäs M; Ringborg U
    J Natl Cancer Inst; 1997 May; 89(10):697-702. PubMed ID: 9168184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells.
    Drexler HG
    Leukemia; 1998 Jun; 12(6):845-59. PubMed ID: 9639410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDKN2A, CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours.
    Rousseau E; Ruchoux MM; Scaravilli F; Chapon F; Vinchon M; De Smet C; Godfraind C; Vikkula M
    Neuropathol Appl Neurobiol; 2003 Dec; 29(6):574-83. PubMed ID: 14636164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma.
    Prins JB; Williamson KA; Kamp MM; Van Hezik EJ; Van der Kwast TH; Hagemeijer A; Versnel MA
    Int J Cancer; 1998 Feb; 75(4):649-53. PubMed ID: 9466670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of chromosome arm 9p DNA and analysis of the p16 and p15 cyclin-dependent kinase inhibitor genes in human parathyroid adenomas.
    Tahara H; Smith AP; Gaz RD; Arnold A
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3663-7. PubMed ID: 8855819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.